Wienkers L C, Wurden C J, Storch E, Kunze K L, Rettie A E, Trager W F
Department of Medicinal Chemistry, University of Washington, Seattle 98195, USA.
Drug Metab Dispos. 1996 May;24(5):610-4.
Kinetic studies demonstrate that two forms of human liver cytochrome P450 are responsible for the formation of (R)-8-hydroxywarfarin: a low-affinity enzyme (KM approximately 1.5 mM), previously identified as P4501A2; and a high-affinity enzyme (KM = 330 microM), now identified as P4502C19 on the basis of the following evidence. In crossover inhibition studies with P4501A2-depleted human liver microsomes between (R)-warfarin and (S)-mephenytoin, reciprocal competitive inhibition was observed. Apparent KM values for (S)-mephenytoin-4'-hydroxylation (52-67 microM) were similar to the determined Ki values (58-62 microM) for (S)-mephenytoin inhibition of (R)-8-hydroxywarfarin formation. Similarly, the apparent KM for (R)-warfarin 8-hydroxylation in furafylline-pretreated microsomes (KM = 289-395 microM) was comparable with the Ki values (280-360 microM) for (R)-warfarin inhibition of (S)-4'-hydroxymephenytoin formation. Inhibition studies with tranylcypromine, a known inhibitor of (S)-mephenytoin hydroxylase activity, and either substrate in three different microsomal preparations yielded nearly identical inhibitory constants: Ki = 8.7 +/- 1.6 microM for inhibition of (S)-4'-hydroxymephenytoin formation and 8.8 +/- 2.5 microM for inhibition of (R)-8-hydroxywarfarin formation. In addition, fluconazole, a potent inhibitor of (R)-warfarin 8-hydroxylation, Ki = 2 microM, was found to inhibit (S)-mephenytoin hydroxylation with an identical Ki (2 microM). Finally, a strong correlation between (S)-mephenytoin 4-hydroxylation and (R)-warfarin 8-hydroxylation activities in furafylline-pretreated microsomes was demonstrated in 14 human liver microsomal preparations (r2 = 0.97).
动力学研究表明,人肝脏细胞色素P450的两种形式负责(R)-8-羟基华法林的形成:一种低亲和力酶(Km约为1.5 mM),先前已鉴定为P4501A2;以及一种高亲和力酶(Km = 330 microM),基于以下证据现在鉴定为P4502C19。在用(R)-华法林和(S)-美芬妥英在P4501A2耗尽的人肝微粒体中进行的交叉抑制研究中,观察到相互竞争性抑制。(S)-美芬妥英-4'-羟基化的表观Km值(52-67 microM)与(S)-美芬妥英对(R)-8-羟基华法林形成抑制的测定Ki值(58-62 microM)相似。同样,在呋喃茶碱预处理的微粒体中(R)-华法林8-羟基化的表观Km(Km = 289-395 microM)与(R)-华法林对(S)-4'-羟基美芬妥英形成抑制的Ki值(280-360 microM)相当。用反苯环丙胺(一种已知的(S)-美芬妥英羟化酶活性抑制剂)与三种不同微粒体制剂中的任何一种底物进行的抑制研究产生了几乎相同的抑制常数:抑制(S)-4'-羟基美芬妥英形成的Ki = 8.7 +/- 1.6 microM,抑制(R)-8-羟基华法林形成的Ki = 8.8 +/- 2.5 microM。此外,发现氟康唑(一种(R)-华法林8-羟基化的有效抑制剂,Ki = 2 microM)以相同的Ki(2 microM)抑制(S)-美芬妥英羟化。最后,在14种人肝微粒体制剂中证明了呋喃茶碱预处理的微粒体中(S)-美芬妥英4-羟基化与(R)-华法林8-羟基化活性之间的强相关性(r2 = 0.97)。